MCID: CCN001
MIFTS: 48

Cocaine Dependence

Categories: Mental diseases

Aliases & Classifications for Cocaine Dependence

MalaCards integrated aliases for Cocaine Dependence:

Name: Cocaine Dependence 12 75 55 15 17 72

Classifications:



External Ids:

Disease Ontology 12 DOID:9975
ICD9CM 35 304.2 304.20
MeSH 44 D019970
NCIt 50 C34492
SNOMED-CT 68 31956009
ICD10 33 F14.2
UMLS 72 C0600427

Summaries for Cocaine Dependence

Disease Ontology : 12 A drug dependence that is a psychological dependency on the regular use of cocaine.

MalaCards based summary : Cocaine Dependence is related to cocaine abuse and personality disorder. An important gene associated with Cocaine Dependence is DRD2 (Dopamine Receptor D2), and among its related pathways/superpathways are Transmission across Chemical Synapses and Circadian entrainment. The drugs Carbamazepine and Modafinil have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and testes, and related phenotypes are behavior/neurological and growth/size/body region

Wikipedia : 75 Cocaine dependence is a psychological desire to use cocaine regularly. Cocaine overdose may result in... more...

Related Diseases for Cocaine Dependence

Diseases related to Cocaine Dependence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 105)
# Related Disease Score Top Affiliating Genes
1 cocaine abuse 31.1 SLC6A4 SLC6A3 DRD2 DBH
2 personality disorder 30.9 SLC6A4 SLC6A3 HTR1B DRD2
3 antisocial personality disorder 30.7 SLC6A4 SLC6A3 HTR1B DRD2
4 heroin dependence 30.6 PDYN OPRM1 DRD2
5 polysubstance abuse 30.6 DRD3 DRD2
6 bipolar disorder 30.6 SLC6A4 SLC6A3 DRD3 DRD2
7 psychotic disorder 30.5 SLC6A4 SLC6A3 DRD3 DRD2 DRD1
8 smoking as a quantitative trait locus 3 30.4 CHRNA5 CHRNA3
9 withdrawal disorder 30.3 POMC PDYN OPRM1
10 substance abuse 30.2 SLC6A4 SLC6A3 HTR1B DRD3 DRD2 DBH
11 social phobia 30.2 SLC6A4 DRD2
12 alexithymia 30.2 SLC6A4 DRD2
13 movement disease 30.1 SLC6A3 DRD3 DRD2
14 schizoaffective disorder 30.1 SLC6A4 DRD3 DRD2
15 opioid abuse 30.0 PDYN OPRM1 DRD2
16 eating disorder 29.9 SLC6A4 SLC6A3 POMC DRD2
17 conduct disorder 29.7 SLC6A4 SLC6A3 DRD2 DBH
18 mood disorder 29.7 SLC6A4 POMC HTR1B DRD3 DRD2
19 major depressive disorder 29.5 SLC6A4 SLC6A3 POMC HTR1B DRD3 DRD2
20 opiate dependence 29.3 SLC6A4 POMC PDYN OPRM1 OPRK1 DRD3
21 pathological gambling 29.2 SLC6A4 SLC6A3 DRD3 DRD2 DRD1
22 drug dependence 28.5 SLC6A4 POMC PDYN OPRM1 OPRK1 DRD3
23 attention deficit-hyperactivity disorder 28.2 SLC6A4 SLC6A3 OPRM1 HTR1B DRD3 DRD2
24 tobacco addiction 28.2 SLC6A4 SLC6A3 OPRM1 DRD2 CHRNB3 CHRNA5
25 schizophrenia 28.1 SLC6A4 SLC6A3 HTR1B DRD3 DRD2 DRD1
26 obsessive-compulsive disorder 27.7 SLC6A4 SLC6A3 PDYN HTR1B DRD3 DRD2
27 substance dependence 27.3 SLC6A4 SLC6A3 POMC OPRM1 OPRK1 HTR1B
28 alcohol dependence 26.9 SLC6A4 SLC6A3 POMC PDYN OPRM1 OPRK1
29 cocaine intoxication 11.6
30 tic disorder 10.7 SLC6A3 DRD2
31 delusional disorder 10.5 DRD3 DRD2
32 tardive dyskinesia 10.5 DRD3 DRD2
33 impulse control disorder 10.5 DRD3 DRD2
34 striatonigral degeneration 10.4 SLC6A3 DRD2
35 periodic limb movement disorder 10.4 SLC6A4 DRD2
36 alcohol-induced mental disorder 10.4 SLC6A4 SLC6A3 DRD2
37 alcoholic psychosis 10.4 SLC6A4 SLC6A3 DRD2
38 avoidant personality disorder 10.4
39 restless legs syndrome 10.3 SLC6A3 DRD3 DRD2
40 migraine without aura 10.3 SLC6A4 DRD3 DRD2
41 cutaneous solitary mastocytoma 10.3 POMC PDYN
42 depression 10.3
43 stuttering 10.3 SLC6A3 DRD2 DBH
44 mental depression 10.3
45 multiple system atrophy 1 10.3 SLC6A3 DRD2 DBH
46 functioning pituitary adenoma 10.3 POMC DRD2
47 major affective disorder 8 10.3
48 major affective disorder 9 10.3
49 cannabis dependence 10.3
50 severe combined immunodeficiency 10.3

Graphical network of the top 20 diseases related to Cocaine Dependence:



Diseases related to Cocaine Dependence

Symptoms & Phenotypes for Cocaine Dependence

MGI Mouse Phenotypes related to Cocaine Dependence:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.32 CHRNA3 CHRNA5 CHRNB3 DBH DRD1 DRD2
2 growth/size/body region MP:0005378 10.14 CHRNA3 DBH DRD1 DRD2 DRD3 HTR1B
3 homeostasis/metabolism MP:0005376 10.11 CHRNA3 DBH DRD1 DRD2 DRD3 OPRK1
4 adipose tissue MP:0005375 10.1 DBH DRD1 DRD2 DRD3 HTR1B OPRM1
5 endocrine/exocrine gland MP:0005379 10.03 DBH DRD2 HTR1B OPRK1 OPRM1 POMC
6 digestive/alimentary MP:0005381 10 CHRNA3 DRD1 DRD2 DRD3 OPRK1 OPRM1
7 integument MP:0010771 9.97 DBH DRD1 DRD2 OPRK1 OPRM1 PDYN
8 mortality/aging MP:0010768 9.96 CHRNA3 DBH DRD1 DRD2 DRD3 HTR1B
9 nervous system MP:0003631 9.73 CHRNA3 CHRNA5 DBH DRD1 DRD2 DRD3
10 muscle MP:0005369 9.63 CHRNA3 DRD1 DRD2 HTR1B SLC6A3 SLC6A4
11 no phenotypic analysis MP:0003012 9.1 CHRNA3 DRD2 HTR1B OPRM1 PDYN POMC

Drugs & Therapeutics for Cocaine Dependence

Drugs for Cocaine Dependence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 291)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
2
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
3
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
4
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
5
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
6
Choline Approved, Nutraceutical Phase 4 62-49-7 305
7 Sodium Channel Blockers Phase 4
8 Cytochrome P-450 CYP3A Inducers Phase 4
9 Analgesics, Non-Narcotic Phase 4
10 Cytochrome P-450 Enzyme Inducers Phase 4
11 Serotonin Antagonists Phase 4
12 Serotonin Agents Phase 4
13 Antipsychotic Agents Phase 4
14 Wakefulness-Promoting Agents Phase 4
15 Dopamine Antagonists Phase 4
16 Gastrointestinal Agents Phase 4
17 calcium channel blockers Phase 4
18 Calcium, Dietary Phase 4
19 Diuretics, Potassium Sparing Phase 4
20 Antimetabolites Phase 4
21 Quetiapine Fumarate Phase 4 111974-72-2
22 Hypolipidemic Agents Phase 4
23 Lipid Regulating Agents Phase 4
24 Cytidine Diphosphate Choline Phase 4
25 Lecithin Phase 4
26
Selegiline Approved, Investigational, Vet_approved Phase 3 14611-51-9 5195 26757
27
Citalopram Approved Phase 2, Phase 3 59729-33-8 2771
28
Naltrexone Approved, Investigational, Vet_approved Phase 3 16590-41-3 5360515
29
Biperiden Approved, Investigational Phase 2, Phase 3 514-65-8 2381
30
Caffeine Approved Phase 2, Phase 3 58-08-2 2519
31
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 2, Phase 3 52485-79-7 40400 644073
32
Levodopa Approved Phase 2, Phase 3 59-92-7 6047
33
Carbidopa Approved Phase 2, Phase 3 28860-95-9 34359
34
Mifepristone Approved, Investigational Phase 2, Phase 3 84371-65-3 55245
35
Mirtazapine Approved Phase 2, Phase 3 61337-67-5, 85650-52-8 4205
36
Nicotine Approved Phase 3 54-11-5 942 89594
37
Progesterone Approved, Vet_approved Phase 2, Phase 3 57-83-0 5994
38
Naloxone Approved, Vet_approved Phase 2, Phase 3 465-65-6 5284596
39
Entacapone Approved, Investigational Phase 2, Phase 3 130929-57-6 5281081
40
Bupropion Approved Phase 2, Phase 3 34841-39-9, 34911-55-2 444
41
Methadone Approved, Illicit Phase 2, Phase 3 76-99-3 4095
42
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
43 Parasympatholytics Phase 2, Phase 3
44 Serotonin Uptake Inhibitors Phase 2, Phase 3
45 Serotonin Receptor Agonists Phase 2, Phase 3
46 Muscarinic Antagonists Phase 2, Phase 3
47 Cholinergic Antagonists Phase 2, Phase 3
48 Antiparkinson Agents Phase 2, Phase 3
49 Neuroprotective Agents Phase 3
50 Monoamine Oxidase Inhibitors Phase 3

Interventional clinical trials:

(show top 50) (show all 309)
# Name Status NCT ID Phase Drugs
1 Efficacy of Caffeine, With and Without Biperiden, as a Maintenance Treatment for Cocaine Dependence Unknown status NCT00495183 Phase 4 caffeine;Biperiden;Placebo
2 Pathophysiological Subtyping of Abnormalities in Cocaine Dependence Completed NCT00015275 Phase 4
3 Pharmacotherapy and Intensive Treatment Completed NCT00000218 Phase 4 Carbamazepine
4 Efficacy of Quetiapine in the Reduction of Cocaine Use and Cravings in Individuals With Cocaine Dependence Completed NCT00232336 Phase 4 quetiapine
5 A Randomized, Double-blind, Placebo-controlled, Trial of Lamotrigine add-on Therapy in Outpatients With Bipolar Disorder, Depressed or Mixed Phase and Cocaine Dependence Completed NCT00280293 Phase 4 Lamotrigine;Placebo
6 Effects of Modafinil in Methamphetamine Dependence Completed NCT00751023 Phase 4 Modafinil;Placebo
7 A Randomized, Double-Blind, Placebo-Controlled Add-On Trial of Quetiapine in Patients With Bipolar Disorder and Cocaine Dependence Completed NCT00223210 Phase 4 Quetiapine;PLacebo
8 Seroquel (Quetiapine) Therapy for Schizophrenia and Schizoaffective Disorders and Comorbid Cocaine and/or Amphetamine Abuse/Dependence: A Comparative Study With Risperidone Completed NCT00208143 Phase 4 Quetiapine;Risperidone
9 A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled Trial of Citicoline as an add-on Therapy Will be Conducted in 200 Outpatients With Bipolar I Disorder and Cocaine Dependence. Completed NCT00619723 Phase 4 Citicoline;Placebo
10 Neuroplasticity Following Theta-Burst Stimulation in Cocaine Use Recruiting NCT02927236 Phase 4
11 Dopamine Beta-hydroxylase Inhibition Induced Blunting of Dopaminergic Response to Psychostimulant Administration. A PET Exploration of the Mechanism of Action of a New Therapeutic Strategy in Cocaine Addicts Withdrawn NCT02134002 Phase 4 Disulfiram;Placebo
12 Medication Development for Cocaine Dependence Unknown status NCT00249691 Phase 3 Topiramate + Cognitive Behavioral Therapy;Placebo + Cognitive Behavioral Therapy
13 Novel Pharmacotherapy for Dual Dependence Unknown status NCT00448825 Phase 3 Topiramate + Cognitive Behavioral Therapy;Placebo + Cognitive Behavioral Therapy
14 Dose Response Trial of Pergolide for Cocaine Dependence Completed NCT00000248 Phase 3 Pergolide
15 Double-Blind, Placebo-Controlled Trial of Selegiline Transdermal System for the Treatment of Cocaine Dependence Completed NCT00032929 Phase 3 Selegiline
16 Investigation of the Effects of Mifepristone (RU486) on Stress Sensitivity and Relapse Prevention in Cocaine Dependent Patients Completed NCT01134198 Phase 2, Phase 3 Mifepristone;placebo
17 Naltrexone and Psychosocial Treatments for the Treatment of Cocaine Dependence Complicated by Alcohol Dependence Completed NCT00167232 Phase 3 Naltrexone
18 Efficacy of Caffeine, With and Without Biperiden, in the Detoxification of Cocaine Dependent Patients Completed NCT00495092 Phase 2, Phase 3 Caffeine;Biperiden;Placebo
19 Multicenter Trial of Combined Pharmacotherapy to Treat Cocaine Dependence Completed NCT01811940 Phase 2, Phase 3 Adderall-ER;Topiramate
20 Investigation of the Effect of Intranasal Oxytocin on Relapse Risk in Cocaine-dependent Patients Completed NCT02255357 Phase 2, Phase 3 Placebo;Intranasal Oxytocin
21 Effect of Nefazodone on Relapse in Females With Cocaine Abuse Completed NCT00000293 Phase 3 Nefazodone
22 Cocaine/Crack Dependence: A Study of the Possible Reduction of Compulsion Under the Use of Biperiden Completed NCT01251393 Phase 3 Biperiden;Placebo
23 Cocaine Use Reduction With Buprenorphine (CURB) Completed NCT01402492 Phase 2, Phase 3 Buprenorphine + Naltrexone;Placebo + Naltrexone
24 Imaging the Neurobiology of Behavioral and Medication Treatment for Cocaine Dependence Completed NCT01468012 Phase 2, Phase 3 levodopa carbidopa and entacapone (LCE);Placebo
25 Dopamine Transporter (DAT) in Pharmacological Treatments of Cocaine Dependence. CAIMAN (Cocaine Addiction Imaging Medications and Neurotransmitters) Study Completed NCT00701532 Phase 3 Modafinil and PET (brain imaging);placebo
26 Naltrexone and Psychosocial Treatments for the Treatment of Cocaine Dependence Complicated by Alcohol Dependence Completed NCT00218660 Phase 3 Naltrexone;Placebo
27 A Randomized, Double-Blind, Placebo-Controlled Study of Mixed Amphetamine Salts (Adderall-XR) for the Treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD) and Cocaine Dependence Completed NCT00553319 Phase 2, Phase 3 Placebo;Adderall-XR;Adderall-XR
28 Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study Completed NCT01281202 Phase 2, Phase 3 Vigabatrin;Matching Placebo
29 Smoking-Cessation and Stimulant Treatment (S-CAST): Evaluation of the Impact of Concurrent Outpatient Smoking-Cessation and Stimulant Treatment on Stimulant-Dependence Outcomes Completed NCT01077024 Phase 3
30 Project 1: Clinical Neurobiology of Serotonin and Addiction Completed NCT00732901 Phase 2, Phase 3 Escitalopram;Placebo
31 Progesterone Treatment for Cocaine-dependent Women: A Pilot Study Completed NCT00632099 Phase 2, Phase 3 Oral micronized progesterone;Placebo
32 A Proof of Concept Study of Icariin for Bipolar Disorder and Co-Occurring Substance Use Disorders Completed NCT01979133 Phase 3 Icariin
33 Adaptive Treatment for Alcohol and Cocaine Dependence Completed NCT01032135 Phase 2, Phase 3 medication management
34 Bupropion-Enhanced CM for Cocaine Dependence Recruiting NCT02111798 Phase 2, Phase 3 Bupropion XL;placebo
35 A Double-Blind, Controlled Study of Aripiprazole in Co-Morbid Schizophrenia and Cocaine Dependence Unknown status NCT00737256 Phase 2 Aripiprazole;Perphenazine
36 Effect of Magnetic Stimulation Repetitive Transcranial on Impulsivity in Cocaine Dependence. Unknown status NCT01397266 Phase 2
37 Randomised Placebo-Controlled Trial of Modafinil for Cocaine Dependence Unknown status NCT00123383 Phase 2 Modafinil
38 Treating Cocaine Abuse: A Behavioral Approach Unknown status NCT01822327 Phase 2
39 Effect of Repetitive Transcranial Magnetic Stimulation on Symptoms of Attention Deficit Hyperactivity Disorder and Cognitive Function In Cocaine Addicts Unknown status NCT01593982 Phase 2
40 Double-Blind, Placebo-Controlled Trial of N-acetylcysteine (NAC) for the Treatment of Pediatric Obsessive-Compulsive Disorder Unknown status NCT01172275 Phase 2 N-Acetylcysteine;Placebo
41 Lidocaine Infusion as a Treatment for Cocaine Relapse and Craving Unknown status NCT01929343 Phase 2 lidocaine following cue-induced craving;lidocaine following neutral stimulus;saline
42 Carbamazepine Treatment for Cocaine Dependence Completed NCT00000191 Phase 2 Carbamazepine
43 Selegiline in Treatment of Cocaine Dependence Completed NCT00000188 Phase 2 Selegiline
44 Ritanserin in Treatment of Cocaine Dependence Completed NCT00000187 Phase 2 Ritanserin
45 Modafinil for the Treatment of Cocaine Dependence Completed NCT00100100 Phase 2 Modafinil
46 Multi-Center Trial of Baclofen for the Treatment of Cocaine Dependence Completed NCT00082485 Phase 2 Baclofen
47 A Double-Blind, Placebo-Controlled Study of the Effects of Risperdal Consta on Brain Reward Circuitry, Craving and Cocaine Use in Active Cocaine Dependence Completed NCT00385801 Phase 2 Risperidone;Placebo
48 Serotonin, Impulsivity, and Cocaine Dependence Treatment Completed NCT00297505 Phase 2 citalopram
49 Risperidone for the Treatment of Cocaine Dependence Completed NCT00000342 Phase 2 Risperidone
50 Double-Blind, Placebo-Controlled Trial of Ondansetron for the Treatment of Cocaine Dependence Completed NCT00033085 Phase 2 Ondansetron

Search NIH Clinical Center for Cocaine Dependence

Genetic Tests for Cocaine Dependence

Anatomical Context for Cocaine Dependence

MalaCards organs/tissues related to Cocaine Dependence:

41
Brain, Heart, Testes, Cortex, Prefrontal Cortex, Pituitary, Amygdala

Publications for Cocaine Dependence

Articles related to Cocaine Dependence:

(show top 50) (show all 1643)
# Title Authors PMID Year
1
Association analysis between polymorphisms in the dopamine D2 receptor (DRD2) and dopamine transporter (DAT1) genes with cocaine dependence. 9 38
20170711 2010
2
Association analysis between polymorphisms in the dopamine D3 receptor (DRD3) gene and cocaine dependence. 9 38
19503018 2009
3
mechanisms of disulfiram-induced cocaine abstinence: antabuse and cocaine relapse. 9 38
19720750 2009
4
Response to corticotropin-releasing hormone infusion in cocaine-dependent individuals. 9 38
19349312 2009
5
A functional haplotype implicated in vulnerability to develop cocaine dependence is associated with reduced PDYN expression in human brain. 9 38
18923396 2009
6
Relationship of the serotonin transporter with prolactin response to meta-chlorophenylpiperazine in cocaine dependence. 9 38
18321529 2008
7
Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity? 9 38
15988468 2005
8
Relationship between serotonin transporter gene polymorphisms and platelet serotonin transporter sites among African-American cocaine-dependent individuals and healthy volunteers. 9 38
15091312 2004
9
Gene-environment interplay in alcoholism and other substance abuse disorders: expressions of heritability and factors influencing vulnerability. 9 38
15545018 2004
10
Dopamine transporter as target for drug development of cocaine dependence medications. 9 38
14612141 2003
11
No association between polymorphisms in the serotonin transporter gene and susceptibility to cocaine dependence among African-American individuals. 9 38
12218660 2002
12
Sequence variability and candidate gene analysis in complex disease: association of mu opioid receptor gene variation with substance dependence. 9 38
11092766 2000
13
PET studies of brain monoamine transporters. 9 38
10974156 2000
14
Family-based study of DRD2 alleles in alcohol and drug dependence. 9 38
11054774 2000
15
Homozygosity at the dopamine DRD3 receptor gene in cocaine dependence. 9 38
10523822 1999
16
No association between D2 dopamine receptor (DRD2) alleles or haplotypes and cocaine dependence or severity of cocaine dependence in European- and African-Americans. 9 38
10023512 1999
17
Are neuroadaptations in D3 dopamine receptors linked to the development of cocaine dependence? 9 38
9154209 1997
18
No association between D3 dopamine receptor (DRD3) alleles and cocaine dependence. 9 38
12893467 1996
19
Genetic association between dopamine transporter protein alleles and cocaine-induced paranoia. 9 38
7865100 1994
20
Allelic association of the D2 dopamine receptor gene with cocaine dependence. 9 38
8261891 1993
21
Web-based self-help with and without chat counseling to reduce cocaine use in cocaine misusers: Results of a three-arm randomized controlled trial. 38
31193584 2019
22
Genome-wide association meta-analysis of cocaine dependence: Shared genetics with comorbid conditions. 38
31212010 2019
23
Hypothalamic Responses to Cocaine and Food Cues in Individuals with Cocaine Dependence. 38
31420667 2019
24
Motivational factors modulate left frontoparietal network during cognitive control in cocaine addiction. 38
31436010 2019
25
Randomized controlled trial of d-cycloserine in cocaine dependence: Effects on contingency management and cue-induced cocaine craving in a naturalistic setting. 38
31368770 2019
26
Are trait impulsivity and exposure to cannabis or alcohol associated with the age of trajectory of cocaine use? A gender-specific dimensional analysis in humans with cocaine dependence diagnosis. 38
31424236 2019
27
Identifying cognitive deficits in cocaine dependence using standard tests and machine learning. 38
31352033 2019
28
Effects of Social Support and 12-Step Involvement on Recovery among People in Continuing Care for Cocaine Dependence. 38
31322037 2019
29
Pharmacogenetic role of dopamine transporter (SLC6A3) variation on response to disulfiram treatment for cocaine addiction. 38
31087723 2019
30
Double-Blind Placebo-Controlled Trial of Galantamine for Methadone-Maintained Individuals With Cocaine Use Disorder: Secondary Analysis of Effects on Illicit Opioid Use. 38
31165574 2019
31
Adulterants in crack cocaine in Brazil. 38
31314858 2019
32
Classification of cocaine-dependent participants with dynamic functional connectivity from functional magnetic resonance imaging data. 38
30957276 2019
33
Multimodal neurocognitive markers of interoceptive tuning in smoked cocaine. 38
30867552 2019
34
A Single Ketamine Infusion Combined With Mindfulness-Based Behavioral Modification to Treat Cocaine Dependence: A Randomized Clinical Trial. 38
31230464 2019
35
Altered fine motor control and manual dexterity in people with cocaine dependence: An observational study. 38
30575048 2019
36
Cocaine-induced changes in the expression of NMDA receptor subunits. 38
31204625 2019
37
Psychiatric factors affecting recovery after a long term treatment program for substance use disorder. 38
31128488 2019
38
Determination of cocaine adulterants in human urine by dispersive liquid-liquid microextraction and high-performance liquid chromatography. 38
31123783 2019
39
Pitolisant and intravenous cocaine self-administration in mice. 38
30771351 2019
40
Pharmacogenetics of Dopamine β-Hydroxylase in cocaine dependence therapy with doxazosin. 38
29498170 2019
41
Genome-wide DNA methylation profile in the peripheral blood of cocaine and crack dependents. 38
31116258 2019
42
Efficacy and cost-effectiveness of an adjunctive personalised psychosocial intervention in treatment-resistant maintenance opioid agonist therapy: a pragmatic, open-label, randomised controlled trial. 38
30952568 2019
43
A critical literature review on emotional intelligence in addiction. 38
30942265 2019
44
HMG-CoA synthase 2 drives brain metabolic reprogramming in cocaine exposure. 38
28987936 2019
45
Cocaine relapse and health-related quality of life: a 23 weeks study. 38
31017271 2019
46
Acceptance and present-moment awareness in psychiatric disorders: Is mindfulness mood dependent? 38
30682558 2019
47
In Cocaine Dependence, Neural Prediction Errors During Loss Avoidance Are Increased With Cocaine Deprivation and Predict Drug Use. 38
30297162 2019
48
fMRI Stroop and behavioral treatment for cocaine-dependence: Preliminary findings in methadone-maintained individuals. 38
30240978 2019
49
Cocaine'omics: Genome-wide and transcriptome-wide analyses provide biological insight into cocaine use and dependence. 38
30734435 2019
50
A positive association between a polymorphism in the HTR2B gene and cocaine-crack in a French Afro-Caribbean population. 38
30608182 2019

Variations for Cocaine Dependence

Expression for Cocaine Dependence

Search GEO for disease gene expression data for Cocaine Dependence.

Pathways for Cocaine Dependence

Pathways related to Cocaine Dependence according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.73 SLC6A4 SLC6A3 CHRNB3 CHRNA5 CHRNA3
2
Show member pathways
12.72 SLC6A3 OPRM1 DRD3 DRD2 DRD1 CHRNA3
3
Show member pathways
12.65 POMC PDYN OPRM1 OPRK1 HTR1B DRD3
5
Show member pathways
11.69 SLC6A3 PDYN DRD2 DRD1
6
Show member pathways
11.6 HTR1B DRD3 DRD2 DRD1
7
Show member pathways
11.54 CHRNB3 CHRNA5 CHRNA3
8
Show member pathways
11.47 DRD3 DRD2 CHRNA5 CHRNA3
9
Show member pathways
11.21 SLC6A4 SLC6A3 DBH
10 10.96 SLC6A4 HTR1B
11
Show member pathways
10.91 SLC6A4 SLC6A3
12 10.47 DRD3 DRD2 DRD1

GO Terms for Cocaine Dependence

Cellular components related to Cocaine Dependence according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 neuron projection GO:0043005 9.88 SLC6A4 SLC6A3 CHRNB3 CHRNA5 CHRNA3
2 neuronal cell body GO:0043025 9.85 SLC6A3 PDYN OPRK1 CHRNA3
3 dendrite GO:0030425 9.8 PDYN OPRM1 OPRK1 HTR1B DRD2 CHRNA3
4 perikaryon GO:0043204 9.71 OPRM1 OPRK1 DRD2
5 GABA-ergic synapse GO:0098982 9.69 DRD3 DRD2 DRD1
6 axon terminus GO:0043679 9.67 PDYN OPRK1 DRD2
7 integral component of postsynaptic membrane GO:0099055 9.63 SLC6A4 SLC6A3 OPRM1 OPRK1 DRD2 DRD1
8 non-motile cilium GO:0097730 9.56 DRD2 DRD1
9 acetylcholine-gated channel complex GO:0005892 9.54 CHRNB3 CHRNA5 CHRNA3
10 serotonergic synapse GO:0099154 9.43 SLC6A4 HTR1B
11 dopaminergic synapse GO:0098691 9.35 SLC6A3 DRD3 DRD2 CHRNB3 CHRNA5
12 integral component of presynaptic membrane GO:0099056 9.17 SLC6A4 SLC6A3 OPRM1 OPRK1 HTR1B DRD2
13 membrane GO:0016020 10.3 SLC6A4 SLC6A3 OPRM1 OPRK1 HTR1B DRD3
14 integral component of membrane GO:0016021 10.23 SLC6A4 SLC6A3 OPRM1 OPRK1 HTR1B DRD3
15 plasma membrane GO:0005886 10.18 SLC6A4 SLC6A3 PDYN OPRM1 OPRK1 HTR1B
16 integral component of plasma membrane GO:0005887 10 SLC6A4 SLC6A3 OPRM1 OPRK1 HTR1B DRD3

Biological processes related to Cocaine Dependence according to GeneCards Suite gene sharing:

(show top 50) (show all 70)
# Name GO ID Score Top Affiliating Genes
1 neuropeptide signaling pathway GO:0007218 9.92 POMC PDYN OPRM1 OPRK1
2 regulation of membrane potential GO:0042391 9.9 CHRNB3 CHRNA5 CHRNA3
3 memory GO:0007613 9.87 SLC6A4 DRD1 DBH
4 chemical synaptic transmission GO:0007268 9.87 PDYN OPRK1 HTR1B DBH CHRNB3 CHRNA5
5 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.85 OPRM1 HTR1B DRD1
6 adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway GO:0007193 9.85 OPRM1 OPRK1 HTR1B
7 visual learning GO:0008542 9.85 DRD3 DRD2 DRD1 DBH
8 nervous system process GO:0050877 9.84 CHRNB3 CHRNA5 CHRNA3
9 excitatory postsynaptic potential GO:0060079 9.83 OPRM1 DRD2 CHRNB3 CHRNA5 CHRNA3
10 neuromuscular synaptic transmission GO:0007274 9.82 CHRNB3 CHRNA5 CHRNA3
11 feeding behavior GO:0007631 9.81 HTR1B DRD2 DRD1
12 associative learning GO:0008306 9.81 DRD2 DRD1 DBH
13 response to amphetamine GO:0001975 9.81 DRD3 DRD2 DRD1 DBH
14 synaptic transmission, cholinergic GO:0007271 9.8 CHRNB3 CHRNA5 CHRNA3
15 synaptic transmission, dopaminergic GO:0001963 9.79 DRD3 DRD2 DRD1
16 dopamine receptor signaling pathway GO:0007212 9.78 DRD3 DRD2 DRD1
17 response to morphine GO:0043278 9.78 OPRM1 OPRK1 DRD3 DRD2
18 dopamine metabolic process GO:0042417 9.77 DRD3 DRD2 DRD1
19 maternal behavior GO:0042711 9.77 OPRK1 DRD1 DBH
20 regulation of synaptic vesicle exocytosis GO:2000300 9.77 HTR1B DRD2 DRD1 CHRNB3 CHRNA5
21 behavioral response to cocaine GO:0048148 9.76 OPRK1 DRD3 DRD2 DRD1
22 G protein-coupled receptor internalization GO:0002031 9.75 HTR1B DRD3 DRD2
23 regulation of sensory perception of pain GO:0051930 9.74 OPRM1 OPRK1
24 regulation of dopamine secretion GO:0014059 9.74 HTR1B DRD3
25 adult walking behavior GO:0007628 9.74 DRD2 DRD1
26 positive regulation of neurogenesis GO:0050769 9.74 OPRM1 DRD2
27 negative regulation of blood pressure GO:0045776 9.74 DRD3 DRD2
28 eating behavior GO:0042755 9.74 OPRM1 OPRK1
29 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.74 OPRM1 DRD3 DRD1
30 arachidonic acid secretion GO:0050482 9.73 DRD3 DRD2
31 temperature homeostasis GO:0001659 9.73 DRD2 DRD1
32 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.73 DRD3 DRD2
33 response to iron ion GO:0010039 9.73 SLC6A3 DRD2
34 negative regulation of protein secretion GO:0050709 9.73 DRD3 DRD2
35 vasoconstriction GO:0042310 9.73 SLC6A4 HTR1B
36 behavioral response to ethanol GO:0048149 9.73 OPRM1 DRD2 DBH
37 response to ethanol GO:0045471 9.73 SLC6A3 OPRM1 OPRK1 HTR1B DRD3 DRD2
38 striatum development GO:0021756 9.72 DRD2 DRD1
39 estrous cycle GO:0044849 9.72 OPRM1 OPRK1
40 positive regulation of renal sodium excretion GO:0035815 9.72 DRD3 DRD2
41 neurotransmitter biosynthetic process GO:0042136 9.72 SLC6A4 SLC6A3
42 grooming behavior GO:0007625 9.71 DRD2 DRD1
43 sensory perception GO:0007600 9.71 OPRM1 OPRK1
44 regulation of dopamine metabolic process GO:0042053 9.71 SLC6A3 DRD1
45 peristalsis GO:0030432 9.71 DRD2 DRD1
46 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.71 DRD3 DRD2
47 prepulse inhibition GO:0060134 9.71 SLC6A3 DRD3 DRD2 DRD1
48 opioid receptor signaling pathway GO:0038003 9.7 OPRM1 OPRK1
49 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.7 HTR1B DRD2
50 monoamine transport GO:0015844 9.7 SLC6A4 SLC6A3

Molecular functions related to Cocaine Dependence according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.91 OPRM1 OPRK1 HTR1B DRD3 DRD2 DRD1
2 ion channel activity GO:0005216 9.75 CHRNB3 CHRNA5 CHRNA3
3 extracellular ligand-gated ion channel activity GO:0005230 9.63 CHRNB3 CHRNA5 CHRNA3
4 neuropeptide binding GO:0042923 9.57 OPRM1 OPRK1
5 G-protein alpha-subunit binding GO:0001965 9.56 OPRM1 DRD1
6 adrenergic receptor activity GO:0004935 9.55 DRD3 DRD2
7 neurotransmitter:sodium symporter activity GO:0005328 9.54 SLC6A4 SLC6A3
8 acetylcholine-gated cation-selective channel activity GO:0022848 9.54 CHRNB3 CHRNA5 CHRNA3
9 serotonin binding GO:0051378 9.52 SLC6A4 HTR1B
10 opioid receptor activity GO:0004985 9.51 OPRM1 OPRK1
11 acetylcholine binding GO:0042166 9.5 CHRNB3 CHRNA5 CHRNA3
12 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.49 DRD3 DRD2
13 monoamine transmembrane transporter activity GO:0008504 9.48 SLC6A4 SLC6A3
14 drug binding GO:0008144 9.46 SLC6A3 HTR1B DRD3 DRD2
15 acetylcholine receptor activity GO:0015464 9.43 CHRNB3 CHRNA5 CHRNA3
16 ligand-gated ion channel activity GO:0015276 9.4 CHRNA5 CHRNA3
17 dopamine neurotransmitter receptor activity GO:0004952 9.13 DRD3 DRD2 DRD1
18 dopamine binding GO:0035240 8.92 SLC6A3 DRD3 DRD2 DRD1

Sources for Cocaine Dependence

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....